Fenofibrate/simvastatin
| Combination of | |
|---|---|
| Fenofibrate | Fibrate |
| Simvastatin | Statin |
| Clinical data | |
| Trade names | Cholib |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Fenofibrate/simvastatin, sold under the brand name Cholib, is a combination drug used to treat abnormal blood lipid levels when used in combination with a low-fat diet and exercise.[1]
It was approved for use in the European Union in August 2013.[1]
References
- ^ a b "Cholib EPAR". European Medicines Agency (EMA). 5 March 2020. Retrieved 5 March 2020.
Further reading
- Filippatos TD, Elisaf MS (2015). "Safety considerations with fenofibrate/simvastatin combination". Expert Opin Drug Saf. 14 (9): 1481–93. doi:10.1517/14740338.2015.1056778. PMID 26134595.
- Tarantino N, Santoro F, De Gennaro L, et al. (2017). "Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy". Vasc Health Risk Manag. 13: 29–41. doi:10.2147/VHRM.S95044. PMC 5317328. PMID 28243111.
{{cite journal}}: CS1 maint: unflagged free DOI (link)
External links
- "Fenofibrate". Drug Information Portal. U.S. National Library of Medicine.
- "Simvastatin". Drug Information Portal. U.S. National Library of Medicine.
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |